Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;13(3):373-385.
doi: 10.4103/1673-5374.228711.

Cerebral ischemia and neuroregeneration

Reggie H C Lee  1 , Michelle H H Lee  2 , Celeste Y C Wu  1 , Alexandre Couto E Silva  3 , Harlee E Possoit  1 , Tsung-Han Hsieh  1 , Alireza Minagar  4 , Hung Wen Lin  5
Affiliations
Review

Cerebral ischemia and neuroregeneration

Reggie H C Lee et al. Neural Regen Res. 2018 Mar.

Erratum in

Abstract

Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies against stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.

Keywords: cerebral ischemia; fatty acids; melatonin; neuromodulation therapy; pifithrin-α; protein kinase C; resveratrol; stem cell; sympathetic nervous system; traditional Chinese therapies.

PubMed Disclaimer

Conflict of interest statement

None declared

References

    1. Adkins-Muir DL, Jones TA. Cortical electrical stimulation combined with rehabilitative training: enhanced functional recovery and dendritic plasticity following focal cortical ischemia in rats. Neurol Res. 2003;25:780–788. - PubMed
    1. Allman C, Amadi U, Winkler AM, Wilkins L, Filippini N, Kischka U, Stagg CJ, Johansen-Berg H. Ipsilesional anodal tDCS enhances the functional benefits of rehabilitation in patients after stroke. Sci Transl Med. 2016;8:330re–331. - PMC - PubMed
    1. Amarenco P, Lavallee PC, Labreuche J, Albers GW, Bornstein NM, Canhao P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Skoloudik D, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, Wong LK, Investigators TIo One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;374:1533–1542. - PubMed
    1. Anderson DJ. Stem cells and pattern formation in the nervous system: the possible versus the actual. Neuron. 2001;30:19–35. - PubMed
    1. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive not immune privileged. Nat Biotechnol. 2014;32:252–260. - PMC - PubMed